Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer
A phase 2 trial of Disitamab vedotin, RC148 and Toripalimab in HER2-positive breast cancer, run by RemeGen Co., Ltd., now recruiting.
Overview
Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast Cancer is a phase 2 interventional study registered as NCT06642545 by RemeGen Co., Ltd., with 40 participants planned, started 2025-02-10 and due to reach its primary completion in 2026-10-01. Interventions recorded: Disitamab Vedotin, RC148, Albumin-bound Paclitaxone and Toripalimab.
Similar pages
not linked directly; found by shared links- TrialDV in Combination With Pertuzumab With or Without Toripalimab Neoadjuvant Therapy With HER2-positive Breast Cancer
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
- TrialNeoadjuvant Study of DV in Combination Toripalimab or Sequence Chemotherapy in HR-negative, HER2 Low-expressing Breast Cancer
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
- TrialA Study of RC118 Plus Toripalimab / RC148 in Patients with Locally Advanced Unresectable or Metastatic Solid Tumors
Shares RC148, RemeGen, Toripalimab and the tag pipeline.
- TrialTo Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer
Shares RemeGen, Disitamab vedotin, Toripalimab, HER2-positive breast cancer and the tag pipeline.
- TrialPerioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma.
Shares RemeGen, Disitamab vedotin, Toripalimab and the tag pipeline.
- TrialA Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Shares RemeGen, Disitamab vedotin, HER2-positive breast cancer and the tag pipeline.
- TrialTo Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravesical Instiliations of Disitamab Vedotin in Patients With High-risk Non-muscular Invasive Bladder Cancer (NMIBC) That Express HER2
Shares RemeGen, Disitamab vedotin and the tag pipeline.
- TrialDV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy
Shares RemeGen, Disitamab vedotin and the tag pipeline.